 Quinolines
"Quinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011804
|
| MeSH Number(s) |
D03.633.100.810
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolines".
Below are MeSH descriptors whose meaning is more specific than "Quinolines".
This graph shows the total number of publications written about "Quinolines" by people in this website by year, and whether "Quinolines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 5 | 3 | 8 | | 2007 | 2 | 0 | 2 | | 2008 | 4 | 1 | 5 | | 2009 | 3 | 2 | 5 | | 2010 | 3 | 3 | 6 | | 2011 | 3 | 5 | 8 | | 2012 | 2 | 3 | 5 | | 2013 | 3 | 2 | 5 | | 2014 | 6 | 3 | 9 | | 2015 | 3 | 2 | 5 | | 2016 | 3 | 1 | 4 | | 2017 | 1 | 0 | 1 | | 2018 | 2 | 1 | 3 | | 2019 | 4 | 1 | 5 | | 2020 | 2 | 1 | 3 | | 2021 | 4 | 3 | 7 | | 2022 | 1 | 1 | 2 | | 2023 | 1 | 0 | 1 | | 2024 | 5 | 5 | 10 | | 2025 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Quinolines" by people in Profiles.
-
Dela Cruz FS, Fox E, DuBois SG, Friedman GK, Croop JM, Kim A, Morgenstern DA, Balis FM, Macy ME, Pressey JG, Watt T, Krystal JI, Vo KT, Mody R, Laetsch TW, Weigel BJ, O'Hara K, He CS, Aluri J, Okpara CE, Glade Bender JL. A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatr Blood Cancer. 2025 Jul; 72(7):e31692.
-
Erlandson KM, Umbleja T, Ribaudo HJ, Schrack JA, Overton ET, Fichtenbaum CJ, Fitch KV, Roa JC, Diggs MR, Wood K, Zanni MV, Bloomfield GS, Malvestutto C, Aberg JA, Rodriguez-Barradas MC, Morones RG, Breaux K, Douglas PS, Grinspoon SK, Brown TT. Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clin Infect Dis. 2025 02 24; 80(2):425-433.
-
Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Mar; 194:98-104.
-
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
-
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Ann Am Thorac Soc. 2024 Nov; 21(11):1507-1515.
-
Rothman RL, Stewart TG, Mourad A, Boulware DR, McCarthy MW, Thicklin F, Garcia Del Sol IT, Garcia JL, Bramante CT, Shah NS, Singh U, Williamson JC, Rebolledo PA, Jagannathan P, Schwasinger-Schmidt T, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, DeLong A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Hanna GJ, Shenkman E, Hernandez AF, Naggie S, Lindsell CJ. Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. JAMA Netw Open. 2024 Oct 01; 7(10):e2439332.
-
Gelderblom H, Razak AA, Taylor MH, Bauer TM, Wilky B, Martin-Broto J, Gonzalez AF, Rutkowski P, Szostakowski B, Alcindor T, Saleh R, Genta S, Stacchiotti S, van de Sande M, Wagner AJ, Bernthal N, Davis LE, Vuky J, Tait C, Matin B, Narasimhan S, Sharma MG, Ruiz-Soto R, Sherman ML, Tap WD. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib. Clin Cancer Res. 2024 Sep 13; 30(18):3996-4004.
-
Nilsson T, Rasinski P, Smedby ?, Af Bur?n S, Sparrelid E, L?hr JM, Tran TA, Blomgren A, Tzortzakakis A, Axelsson R, Holstensson M. Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic Patients. J Nucl Med Technol. 2024 Sep 05; 52(3):221-228.
-
French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Sep 03; 30(17):3757-3767.
-
Gonz?lez-Mart?n A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 2024 07; 186:182-190.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|